INOVIO Pharmaceuticals, Inc.
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026 Recurrent Respiratory…
